Repligen To Acquire A Novozymes Facility | Chemical & Engineering News
Volume 89 Issue 45 | p. 13 | Concentrates
Issue Date: November 7, 2011

Repligen To Acquire A Novozymes Facility

Department: Business
Keywords: biologics, cell culture

Repligen is acquiring a Novozymes plant in Lund, Sweden, that manufactures both growth factors used in mammalian cell culture and Protein A affinity ligands used to make monoclonal antibodies. Repligen is paying about $23 million plus potential milestone payments of almost $6 million. The Swedish business is expected to have sales of more than $16 million this year. Repligen, which already sells four forms of Protein A, says the transaction will elevate it into a leading supplier of products for manufacturing biologic drugs.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment